All
  • All
  • Insight
  • Research Services
  • Preclinical CRO
  • Animal Resource Bank
CN
中文 English

Spontaneous activity/open field test

The open field test, also known as the open‑box test, is a method used to assess the spontaneous behavior, exploratory activity, and anxiety levels of laboratory animals in a novel environment. By measuring the frequency and duration of specific behaviors exhibited by the animals in this unfamiliar setting, researchers can evaluate their spontaneous and exploratory responses; the number of urination and defecation episodes serves as an indicator of their anxiety level.


The open-field analysis system is used to observe and study neuropsychiatric changes in experimental animals, as well as their behaviors when exposed to an open environment. For example, animals may exhibit fear of a novel open space, leading them to spend most of their time near the perimeter while venturing less into the central area; however, their exploratory nature can also motivate them to move into the center, allowing researchers to assess the resulting anxiety. Central stimulants can markedly increase spontaneous locomotor activity while reducing exploratory behavior, whereas a specific dose of antipsychotic agents can suppress exploratory behavior without affecting spontaneous activity.

 

Image source:Aniphe BioLab


Image source: Aniphe BioLab

 

Jiangsu Aniphe BioLab Inc., established in 2018, is committed to becoming an internationally renowned preclinical pharmacodynamic evaluation company in the new era of biopharmaceutical development. Aniphe BioLab has built a comprehensive SPF‑grade laboratory animal facility that integrates animal breeding and husbandry, disease model development, and animal experimentation, covering areas such as oncology, neuroscience, and metabolism.

With over 5,000 mouse and rat cages at its disposal, and backed by a highly skilled technical team and an extensive animal resource base, Aniphe Biolaboratory offers a wide array of disease‑specific animal models, including cerebral ischemia–reperfusion models in mice and rats (MACO/R), myocardial infarction and myocardial ischemia models (MI), transverse aortic constriction (TAC) models, patient‑derived xenograft (PDX) tumor models, cell‑line‑derived xenograft (CDX) tumor models, spinal cord injury (SCI) models, epilepsy models, and Alzheimer’s disease (AD) models. We also provide pharmacological and efficacy evaluation services tailored to these disease models. We warmly welcome all clients to contact us for more information!